Novel rare variant associations with late‐life cognitive performance Authors: Alexandra N Regelson, Derek B Archer, Alaina Durant, Shubhabrata Mukherjee, Michael L Lee, Seo‐Eun Choi, Phoebe Scollard, Emily H Trittschuh, Jesse Mez, William S Bush, Amanda B Kuzma, Michael L Cuccaro, Carlos Cruchaga, Lindsay A Farrer, Li‐San Wang, Gerard D Schellenberg, Richard Mayeux, Walter A Kukull, C Dirk Keene, Andrew J Saykin, Sterling C Johnson, Corinne D Engelman, David A Bennett, Lisa L Barnes, Eric B Larson, Kwangsik Nho, Alison M Goate, Alan E Renton, Edoardo Marcora, Brian Fulton‐Howard, Tulsi Patel, Shannon L Risacher, Anita L DeStefano, Julie A Schneider, Mohamad Habes, Sudha Seshadri, Claudia L Satizabal, Pauline Maillard, Arthur W Toga, Karen Crawford Published: 2025 ABSTRACT AbstractBackgroundDespite evidence that Alzheimer’s disease (AD) is highly heritable, there remains substantial “missing” heritability, likely due in part to the effect of rare variants and to the past reliance on case‐control analysis. Here, we leverage powerful endophenotypes of AD (cognitive performance across multiple cognitive domains) in a rare variant analysis to identify novel genetic drivers of cognition in aging and disease.MethodWe leveraged 8 cohorts of cognitive aging with whole genome sequencing data from the AD Sequencing Project to conduct rare variant analyses of multiple domains of cognition (N = 9,317; mean age = 73; 56% female; 52% cognitively unimpaired). Harmonized scores for memory, executive function, and language were derived using confirmatory factor analysis models. Participants genetically similar to the 1000Genomes EUR reference panel were included in analysis. Variants included in the analysis had a minor allele frequency < 0.01, a minor allele count of ≥ 10, and were annotated as a high or moderate impact SNP using VEP. Associations of baseline scores in each cognitive domain were performed using SKAT‐O, including 92,905 rare variants among 16,243 genes. All tests were adjusted for sex, baseline age, sequencing center and platform, and genetic principal components. Correction for multiple comparisons was completed using the Benjamini‐Hochberg false discovery rate (FDR) procedure.Result APOE was associated with baseline memory, language, and executive function, though only memory survived multiple‐test correction (p.FDR = 0.001). Outside of APOE, ITPKB was associated with baseline executive function (p.FDR = 0.048). AKTIP, SHCBP1L, and CCNF showed nominal associations with multiple domains of cognition that did not survive correction for multiple comparisons (p.FDRs<0.07).ConclusionThese results highlight novel rare variants associated with cognition. IPTKB is an AGORA nominated gene target for potential AD treatment. It is important in the regulation of immune cells and displays higher expression in the cortex of AD patients compared to controls. CCNF and AKTIP are brain eQTLs and have differential RNA expression in AD brains. Previously, variants in AKTIP have been associated with educational attainment, intelligence, and memory, while variants in CCNF have been associated with neuritic plaques and neurofibrillary tangles. Future analyses will incorporate longitudinal cognition and expand into additional populations.